Chen, Guan-JhouGuan-JhouChenHSIN-YUN SUNSUI-YUAN CHANGSZU-MIN HSIEHWANG-HUEI SHENGYU-CHUNG CHUANGYU-SHAN HUANGKUAN-YIN LINLiu, Wen-ChunWen-ChunLiuSu, Yi-ChingYi-ChingSuCHIEN-CHING HUNG2023-09-072023-09-072023-08-0416841182https://scholars.lib.ntu.edu.tw/handle/123456789/635185Antiretroviral regimens containing a second-generation integrase strand-transfer inhibitor (INSTI) plus 2 nucleos(t)ide reverse-transcriptase inhibitors (NRTIs) are the recommended therapy for people with HIV (PWH) who are antiretroviral-naïve or on stable antiretroviral therapy (ART) with viral suppression. Real-world data on the virologic effectiveness of co-formulated bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) among PWH with virologic failure while receiving other ART remain sparse.enBictegravir; Dolutegravir; Genetic barrier; Nucleoside reverse-transcriptase inhibitor; Resistance-associated mutation; Salvage therapy; Virologic failure[SDGs]SDG3Effectiveness of second-generation integrase strand-transfer inhibitor-based regimens for antiretroviral-experienced people with HIV who had viral reboundjournal article10.1016/j.jmii.2023.07.013375744352-s2.0-85168347511https://api.elsevier.com/content/abstract/scopus_id/85168347511